NAD+ Supplementation: Separating the Real Science from the Hype

What Is NAD+ and Why Does It Decline?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every cell, essential to energy metabolism (electron carrier in mitochondrial respiration) and signaling/repair functions through NAD+-dependent enzymes:

• —Sirtuins (SIRT1–7) — NAD+-dependent deacetylases that regulate gene expression, DNA repair, mitochondrial biogenesis, and inflammatory signaling
• —PARPs — DNA repair enzymes that consume NAD+ in response to DNA damage; increased DNA damage with age creates elevated PARP activity that draws down NAD+ stores
• —CD38 — an ectoenzyme that increases with age and is a major NAD+ consumer, particularly during chronic inflammation

NAD+ levels decline approximately 50% between young adulthood and mid-life. The hypothesis: if NAD+ decline contributes to mitochondrial dysfunction, reduced sirtuin activity, and impaired DNA repair, then restoring NAD+ pharmacologically might slow or partially reverse those effects.

NMN vs. NR: The Key Precursors

Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) reliably raise blood NAD+ levels in human trials. The critical question: does raising blood NAD+ translate into raising intracellular NAD+ in the tissues that matter — muscle, liver, brain — and does that translate into measurable clinical outcomes?

The Human Clinical Evidence

• —NMN metabolic effects (Yoshino et al., Science 2021) — 250 mg/day for 10 weeks improved skeletal muscle insulin sensitivity in postmenopausal women with prediabetes; tissue-level effect, though modest in a small trial (n=25)
• —NMN exercise performance (2022 RCT) — improved aerobic capacity (VO2 max) and fat utilization at submaximal exercise intensities in recreational runners; statistically significant but small trial
• —NR NAD+ elevation — multiple studies confirm blood NAD+ rises, but one consistent finding: the rise in circulating NAD+ does not always track with intracellular NAD+ in metabolically important tissues
• —NR metabolic outcomes — a 2018 Cell Metabolism study showed increased NAD+ in blood and muscle with trends toward improved mitochondrial function, but no significant changes in insulin sensitivity, body composition, or VO2 max over 12 weeks

IV NAD+: A Different Conversation

High-dose intravenous NAD+ infusions have emerged in concierge wellness at $200–$1,000 per infusion. The evidence base for IV NAD+ in healthy adults pursuing longevity is currently minimal — no published RCTs demonstrating clinical benefit for longevity indications in asymptomatic adults. Anecdotal reports of improved energy and mental clarity are subject to considerable placebo effect.

Lifestyle Alternatives That Support NAD+ Without Supplementation

• —Aerobic exercise — upregulates NAMPT (the rate-limiting enzyme in the NAD+ salvage pathway), increasing intracellular NAD+ biosynthesis in muscle
• —Caloric restriction and fasting — activates AMPK, which upregulates NAMPT; reduces PARP activation by limiting DNA damage
• —Sleep — adequate sleep reduces DNA damage burden, limiting PARP-mediated NAD+ consumption
• —Reducing chronic inflammation — reduces CD38 activity, the major age-associated NAD+ consumer

Recommending NAD+ precursors as a primary longevity intervention before addressing sleep, resistance training, metabolic health, and diet would be getting the order of operations backwards.

Bottom Line

The NAD+ biology is real and the aging rationale is mechanistically sound. The human clinical trials, as of 2025, demonstrate reliable NAD+ elevation and some tissue-level metabolic effects — but do not yet support the broad longevity claims that populate supplement marketing. This is a promising area of research, not a proven intervention. Patients who choose to supplement with NMN or NR are making a reasonable bet on an incomplete evidence base — which is different from making an evidence-based decision. Understanding that distinction is what informed supplementation looks like.

References

1. 1. Imai SI, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464–471.
2. 2. Zhu XH, et al. In vivo NAD assay reveals intracellular NAD contents in healthy human brain. Proc Natl Acad Sci USA. 2015;112(9):2876–2881.
3. 3. Mills KF, et al. Long-term administration of NMN mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795–806.
4. 4. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229.
5. 5. Liao B, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. J Int Soc Sports Nutr. 2021;18(1):54.
6. 6. Dollerup OL, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men. Am J Clin Nutr. 2018;108(2):343–353.
7. 7. Chen AC, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618–1626.